About Bristol-Myers Squibb Company
Pharma portfolio anchored by Eliquis (blood thinner) and Opdivo (immuno-oncology), both facing eventual patent cliffs, while Cobenfy (schizophrenia) and growth assets provide replacement optionality. Yields ~4.6%—among the highest in large-cap pharma. Very low beta (~0.27) but real idiosyncratic risk; pipeline data and patent litigation drive outsized moves.
Pharmaceuticals